Pharmaceutical Manufacturing
New York, New York
2-10 employees
Founded 2019
About Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals is a clinical-stage company developing innovative, rapid-acting therapies for psychiatric and neurological diseases. Leveraging an AI-powered platform, it creates novel drug candidates, including psychedelic-based compounds, targeting conditions like depression and PTSD. The company advances these therapies through clinical trials and partners with larger pharmaceutical firms for late-stage development and commercialization.
Company Classification
Customer Types
B2B
Business Models
ProductsLicensing
Product & Service Types
Novel psychiatric drug candidatesPsychedelic-based therapiesAI-powered drug discovery
Customers
| Customer | Success Story | Source |
|---|---|---|
| AbbVie entered a definitive agreement to acquire Gilgamesh Pharmaceuticals' lead investigational candidate bretisilocin, including an upfront payment and potential milestone payments up to $1.2 billion, and secured rights to additional psychedelic compounds. |
Sign up to Ethos to access the full customer list, plus detailed competitor and product analysis.
Sign up to Ethos